<p><em>擴展合作繼續利用 Congruence 的專有計算藥物發現引擎 Revenir™，以在神經學和免疫學領域提供開發候選藥物</em></p>
<p><em>Congruence 將獲得未披露的預付款以及研發資金、里程碑付款和版税</em></p>
<p>, /PRNewswire/ -- 小野製藥株式會社（總部：日本大阪；總裁兼首席運營官：高野透；&#34;小野&#34;）與 Congruence Therapeutics 今天宣佈，他們通過執行一項新的研究合作協議，擴大了現有的多靶點研究合作伙伴關係，增加了兩個額外的項目。</p>
<p>擴展合作的重點是兩個在神經學和免疫學領域經過臨牀驗證的高價值靶點，Congruence 將主導發現小分子調節劑並將其推進到開發候選藥物階段。小野將有機會獲得獨家全球權利，以進一步開發和商業化根據新協議生成的開發候選藥物。</p>
<p>兩家公司之間的原始合作始於 2024 年 12 月，重點是利用 Congruence 的專有計算引擎 Revenir™，發現針對難以藥物化的癌症靶點突變體的新型小分子修正劑。</p>
<p>&#34;我們很高興能夠與小野擴大合作關係，這是一家全球創新藥物的先驅，&#34;Congruence 的首席科學官 Sharath Hegde 博士表示。&#34;此次擴展證明了我們在現有合作中所做出的重大貢獻，以及我們與小野之間不斷建立的信任和信心。我們期待利用雙方組織的互補優勢，推動重要研究，以造福患者。&#34;</p>
<p>新的合作繼續利用 Congruence 的計算藥物發現引擎 Revenir™，該引擎系統性地捕捉不同功能狀態下蛋白質的生物物理特徵，以實現小分子發現的高度差異化方法。</p>
<p>Congruence 針對 MC4R 缺乏的遺傳性肥胖的全資項目本月進入 1/1b 期臨牀研究。在接下來的幾周內，Congruence 還將為其針對 GBA1 驅動的帕金森病和α1-抗胰蛋白酶缺乏症的每個項目提名開發候選藥物。</p>
<p>&#34;Congruence 的先進計算發現引擎正吸引越來越多的全球關注，其主導項目進入臨牀開發。我們很榮幸與 Congruence 的持續合作正在擴展到包括神經學和免疫學在內的其他優先領域，&#34;小野的企業官/執行董事、發現與研究部的 Seishi Katsumata 表示。&#34;通過這一合作關係，我們將致力於加速藥物開發，以便儘快為有未滿足醫療需求的患者提供創新的新藥。&#34;</p>
<p>根據今天宣佈的新協議，Congruence 將獲得預付款，並有資格在發現、開發、批准和商業化的某些里程碑達成時獲得額外付款——此外，還將根據相關產品的年度淨銷售額獲得分級版税。此外，小野將報銷 Congruence 在擴展合作中所產生的內部和外部研究費用。</p>
<p><strong>關於 Revenir™藥物發現平台</strong></p>
<p>Revenir™是 Congruence 的專有計算藥物發現平台，捕捉蛋白質在不同功能狀態下的動態生物物理變化，提供對蛋白質功能及其調節的獨特見解。通過檢查表面特徵和一系列生物物理描述符，Revenir™預測小分子誘導的基礎生理蛋白狀態的調節。該平台驅動的策略支撐了 Congruence 日益增長的首創和最佳項目管線，針對與顯著未滿足醫療需求相關的基因驗證靶點，支持一個易於擴展和可重複的價值創造範式。</p>
<p><strong>關於 Congruence Therapeutics</strong></p>
<p>Congruence 是一家以計算為驅動的生物技術公司，正在建立一條獨特的轉化小分子修正劑管線，合理設計以恢復異常蛋白功能。我們的專有可擴展平台 Revenir™捕捉蛋白質在其構象集合中的生物物理特徵，以識別新型別構和隱秘口袋，這些口袋經過虛擬篩選以生成新化學物質。Congruence 利用其專有發現引擎推出了一條針對高價值、基因驗證、難以藥物化靶點的全資藥物管線，涵蓋包括遺傳性肥胖、GBA 帕金森病和α1-抗胰蛋白酶缺乏症在內的多種適應症。Congruence 還在進一步部署其發現平台，以支持與大型製藥公司進行的多靶點研究合作，專注於發現小分子修正劑和別構調節劑，用於治療腫瘤學、代謝疾病、神經學和免疫學領域的疾病。</p>
<p><strong>關於小野製藥株式會社</strong></p>
<p>小野製藥株式會社為全球患者提供創新療法。秉持 “致力於與疾病和疼痛作鬥爭” 的理念，小野針對包括腫瘤學、免疫學與炎症以及神經學在內的未滿足醫療需求領域，促進與學術界和生物技術組織的合作，以加速藥物發現。通過其子公司 Deciphera Pharmaceuticals，小野正在加速在美國和歐洲的臨牀開發和商業運營，以推動全球業務擴展並進一步承諾於患者護理。有關更多信息，請訪問公司網站 https://www.ono-pharma.com/en。</p>
<p><strong>公司聯繫方式</strong> 查爾斯·格魯布斯坦</p>
<p>首席運營官</p>
<p>[email protected]</p>
<p><strong>媒體聯繫方式</strong> 艾米·康拉德</p>
<p>Juniper Point</p>
<p>[email protected]</p>
<p>858-366-3243</p>
<p>來源：Congruence Therapeutics</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzAyJk5ld3NJdGVtSWQ9Tlk5OTQ1NyZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDIxNzAwUFJfTkVXU19VU1BSX19fX19OWTk5NDU3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzAyJk5ld3NJdGVtSWQ9Tlk5OTQ1NyZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDIxNzAwUFJfTkVXU19VU1BSX19fX19OWTk5NDU3"/></p>

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

生物科技 ETF - VanEck Vectors

<p>小野製藥與 Congruence Therapeutics 擴大了他們的多靶點研究合作伙伴關係，新增了兩個專注於神經學和免疫學的新項目。Congruence 將主導小分子調節劑的發現，而小野製藥則有權選擇獨家全球開發和商業化這些候選藥物的權利。此次合作利用了 Congruence 的 Revenir™計算藥物發現引擎。Congruence 將獲得預付款、里程碑付款以及基於淨銷售額的版税。該合作旨在加速滿足未滿足醫療需求患者的藥物開發</p>

<p><em>Expanded collaboration continues to leverage Congruence's proprietary computational</em> <em>drug discovery engine, Revenir™ to deliver Development Candidates in Neurology and Immunology</em></p>
<div class="lb-trans"><p><em>擴展合作繼續利用 Congruence 的專有計算藥物發現引擎 Revenir™，以在神經學和免疫學領域提供開發候選藥物</em></p>
</div><p><em>Congruence to receive undisclosed upfront payment as well as R&amp;D funding, milestones and royalties</em></p>
<div class="lb-trans"><p><em>Congruence 將獲得未披露的預付款以及研發資金、里程碑付款和版税</em></p>
</div><p>, /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; &#34;Ono&#34;) and Congruence Therapeutics today announced that they have expanded their existing multi-target research partnership through the execution of a new research collaboration for two additional programs.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 小野製藥株式會社（總部：日本大阪；總裁兼首席運營官：高野透；&#34;小野&#34;）與 Congruence Therapeutics 今天宣佈，他們通過執行一項新的研究合作協議，擴大了現有的多靶點研究合作伙伴關係，增加了兩個額外的項目。</p>
</div><p>The expanded collaboration is focused on two clinically validated high-value targets in the areas of neurology and immunology for which Congruence will lead the effort to discover small molecule modulators and advance them to the development candidate stage. Ono will have the option to secure exclusive worldwide rights to further develop and commercialize development candidates generated under the new agreement.</p>
<div class="lb-trans"><p>擴展合作的重點是兩個在神經學和免疫學領域經過臨牀驗證的高價值靶點，Congruence 將主導發現小分子調節劑並將其推進到開發候選藥物階段。小野將有機會獲得獨家全球權利，以進一步開發和商業化根據新協議生成的開發候選藥物。</p>
</div><p>An original collaboration between the companies, which began in December 2024, is focused on leveraging Congruence's proprietary computational engine, Revenir™, to discover novel small molecule correctors directed to mutants of a difficult-to-drug cancer target.</p>
<div class="lb-trans"><p>兩家公司之間的原始合作始於 2024 年 12 月，重點是利用 Congruence 的專有計算引擎 Revenir™，發現針對難以藥物化的癌症靶點突變體的新型小分子修正劑。</p>
</div><p>&#34;We are excited to expand our partnership with Ono, a global pioneer of innovative medicines,&#34; said Sharath Hegde PhD, Chief Scientific Officer of Congruence. &#34;The expansion is a testament to the significant contributions we have made in our existing collaboration as well as the trust and confidence we continue to build with Ono. We look forward to leveraging the complementary strengths of both organizations to advance important research for the benefit of patients.&#34;</p>
<div class="lb-trans"><p>&#34;我們很高興能夠與小野擴大合作關係，這是一家全球創新藥物的先驅，&#34;Congruence 的首席科學官 Sharath Hegde 博士表示。&#34;此次擴展證明了我們在現有合作中所做出的重大貢獻，以及我們與小野之間不斷建立的信任和信心。我們期待利用雙方組織的互補優勢，推動重要研究，以造福患者。&#34;</p>
</div><p>The new collaboration continues to leverage Congruence's computational drug discovery engine, Revenir™, which systematically captures the biophysical features of proteins in different functional states to enable a highly differentiated approach to small-molecule discovery.</p>
<div class="lb-trans"><p>新的合作繼續利用 Congruence 的計算藥物發現引擎 Revenir™，該引擎系統性地捕捉不同功能狀態下蛋白質的生物物理特徵，以實現小分子發現的高度差異化方法。</p>
</div><p>Congruence's wholly owned program directed to MC4R-deficient genetic obesity is entering a Phase 1/1b clinical study this month. In the next few weeks, Congruence will also nominate development candidates for each of its programs directed to GBA1-driven Parkinson's Disease and Alpha-1 Antitrypsin deficiency.</p>
<div class="lb-trans"><p>Congruence 針對 MC4R 缺乏的遺傳性肥胖的全資項目本月進入 1/1b 期臨牀研究。在接下來的幾周內，Congruence 還將為其針對 GBA1 驅動的帕金森病和α1-抗胰蛋白酶缺乏症的每個項目提名開發候選藥物。</p>
</div><p>&#34;Congruence's advanced computational discovery engine is attracting growing global attention with its lead program entering clinical development. We are honored that our ongoing collaboration with Congruence is expanding beyond oncology to other priority areas including both neurology and immunology,&#34; said Seishi Katsumata, Corporate Officer / Executive Director, Discovery &amp; Research of Ono. &#34;Through this partnership, we will be committed to accelerating the drug development so that we can deliver innovative new medicines to patients with unmet medical needs as quickly as possible.&#34;</p>
<div class="lb-trans"><p>&#34;Congruence 的先進計算發現引擎正吸引越來越多的全球關注，其主導項目進入臨牀開發。我們很榮幸與 Congruence 的持續合作正在擴展到包括神經學和免疫學在內的其他優先領域，&#34;小野的企業官/執行董事、發現與研究部的 Seishi Katsumata 表示。&#34;通過這一合作關係，我們將致力於加速藥物開發，以便儘快為有未滿足醫療需求的患者提供創新的新藥。&#34;</p>
</div><p>Under the terms of the new agreement announced today, Congruence will receive an upfront payment and is eligible to receive additional payments upon the achievement of certain milestones in discovery, development, approval and commercialization – in addition to tiered royalties based on annual net sales of related products. Moreover, Ono will reimburse Congruence for the internal and external research costs it incurs in connection with the activities undertaken in the expanded partnership.</p>
<div class="lb-trans"><p>根據今天宣佈的新協議，Congruence 將獲得預付款，並有資格在發現、開發、批准和商業化的某些里程碑達成時獲得額外付款——此外，還將根據相關產品的年度淨銷售額獲得分級版税。此外，小野將報銷 Congruence 在擴展合作中所產生的內部和外部研究費用。</p>
</div><p><strong>About Revenir™ Drug Discovery Platform</strong></p>
<div class="lb-trans"><p><strong>關於 Revenir™藥物發現平台</strong></p>
</div><p>Revenir™, Congruence's proprietary computational drug discovery platform, captures the dynamic biophysical changes of proteins in different functional states, offering unique insights into protein function and their modulation. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, Revenir™ predicts small molecule induced modulation of underlying physiologic protein states. This platform-driven strategy underpins Congruence's growing pipeline of first-in-class and best-in-class programs directed to genetically validated targets implicated in conditions associated with significant unmet medical need, supporting a readily scalable and repeatable value creation paradigm.</p>
<div class="lb-trans"><p>Revenir™是 Congruence 的專有計算藥物發現平台，捕捉蛋白質在不同功能狀態下的動態生物物理變化，提供對蛋白質功能及其調節的獨特見解。通過檢查表面特徵和一系列生物物理描述符，Revenir™預測小分子誘導的基礎生理蛋白狀態的調節。該平台驅動的策略支撐了 Congruence 日益增長的首創和最佳項目管線，針對與顯著未滿足醫療需求相關的基因驗證靶點，支持一個易於擴展和可重複的價值創造範式。</p>
</div><p><strong>About Congruence Therapeutics</strong></p>
<div class="lb-trans"><p><strong>關於 Congruence Therapeutics</strong></p>
</div><p>Congruence is a computationally driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson's Disease, and α1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support its multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors and allosteric modulators for the treatment of diseases in oncology, metabolic disease, neurology and immunology.</p>
<div class="lb-trans"><p>Congruence 是一家以計算為驅動的生物技術公司，正在建立一條獨特的轉化小分子修正劑管線，合理設計以恢復異常蛋白功能。我們的專有可擴展平台 Revenir™捕捉蛋白質在其構象集合中的生物物理特徵，以識別新型別構和隱秘口袋，這些口袋經過虛擬篩選以生成新化學物質。Congruence 利用其專有發現引擎推出了一條針對高價值、基因驗證、難以藥物化靶點的全資藥物管線，涵蓋包括遺傳性肥胖、GBA 帕金森病和α1-抗胰蛋白酶缺乏症在內的多種適應症。Congruence 還在進一步部署其發現平台，以支持與大型製藥公司進行的多靶點研究合作，專注於發現小分子修正劑和別構調節劑，用於治療腫瘤學、代謝疾病、神經學和免疫學領域的疾病。</p>
</div><p><strong>About Ono Pharmaceutical Co., Ltd.</strong></p>
<div class="lb-trans"><p><strong>關於小野製藥株式會社</strong></p>
</div><p>Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of &#34;Dedicated to the Fight against Disease and Pain,&#34; Ono targets areas with unmet medical needs including oncology, immunology &amp; inflammation, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.</p>
<div class="lb-trans"><p>小野製藥株式會社為全球患者提供創新療法。秉持 “致力於與疾病和疼痛作鬥爭” 的理念，小野針對包括腫瘤學、免疫學與炎症以及神經學在內的未滿足醫療需求領域，促進與學術界和生物技術組織的合作，以加速藥物發現。通過其子公司 Deciphera Pharmaceuticals，小野正在加速在美國和歐洲的臨牀開發和商業運營，以推動全球業務擴展並進一步承諾於患者護理。有關更多信息，請訪問公司網站 https://www.ono-pharma.com/en。</p>
</div><p><strong>Company Contact</strong> Charles Grubsztajn</p>
<div class="lb-trans"><p><strong>公司聯繫方式</strong> 查爾斯·格魯布斯坦</p>
</div><p>Chief Operating Officer</p>
<div class="lb-trans"><p>首席運營官</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p><strong>Media Contact</strong> Amy Conrad</p>
<div class="lb-trans"><p><strong>媒體聯繫方式</strong> 艾米·康拉德</p>
</div><p>Juniper Point</p>
<div class="lb-trans"><p>Juniper Point</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>858-366-3243</p>
<div class="lb-trans"><p>858-366-3243</p>
</div><p>SOURCE Congruence Therapeutics</p>
<div class="lb-trans"><p>來源：Congruence Therapeutics</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzAyJk5ld3NJdGVtSWQ9Tlk5OTQ1NyZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDIxNzAwUFJfTkVXU19VU1BSX19fX19OWTk5NDU3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY99457&amp;Transmission_Id=202603021700PR_NEWS_USPR_____NY99457&amp;DateId=20260302"/></p>

17:00 ETCongruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs

prnewswire

醫療業 ETF - Vanguard

小野制藥(ADR)

納斯達克生物科技指數 ETF - iShares Nasdaq

醫療業 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

ONO Pharmaceutical Co., Ltd.

美國制藥 ETF - iShares

Invesco Nasdaq Biotechnology ETF

醫藥突破 ETF - ALPS

17:00 ET Congruence 與小野製藥 (ADR) 通過新增兩個項目來擴展多目標研究合作伙伴關係